Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults
NCT07706283, Not applicable, Completed, Barry University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults | ClinicalTrials.gov |
| NCT number | NCT07706283 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 81 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Barry University | ClinicalTrials.gov |
| Conditions | Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function | ClinicalTrials.gov |
| Interventions | Magnesium L-threonate, Placebo | ClinicalTrials.gov |
| First posted | 2026-07-15 | ClinicalTrials.gov |
| Last updated | 2026-07-15 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Baseline (Week 0) and post-intervention (Week 6) | Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI; scored 0-21). Higher scores indicate poorer sleep quality. A score ≥5 indicates poor sleep quality. | ClinicalTrials.gov |
| Primary | Flanker Task Reaction Time | Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit | Reaction time (ms) on the Incongruent Flanker Task assessed via computerized cognitive battery (SOMA platform). Lower values indicate faster processing. | ClinicalTrials.gov |
| Primary | Countermovement Jump Height | Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit | Jump height (cm) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular performance. | ClinicalTrials.gov |
| Secondary | Flanker Task Processing Speed | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Processing speed (1000/RT; s-¹) on the Incongruent Flanker Task. Higher values indicate faster processing. | ClinicalTrials.gov |
| Secondary | Flanker Task Rate Correct Score | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Rate correct score (correct responses·s-¹) on the Incongruent Flanker Task. Higher values indicate better integrated speed-accuracy performance. | ClinicalTrials.gov |
| Secondary | Flanker Task Coefficient of Variation | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Intraindividual response variability (%) on the Incongruent Flanker Task. Lower values indicate more consistent performance. | ClinicalTrials.gov |
| Secondary | Stroop Task Reaction Time | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Reaction time (ms) on the Incongruent Stroop Task assessed via computerized cognitive battery. Lower values indicate faster processing. | ClinicalTrials.gov |
| Secondary | Stroop Task Processing Speed | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Processing speed (1000/RT; s-¹) on the Incongruent Stroop Task. Higher values indicate faster processing. | ClinicalTrials.gov |
| Secondary | Stroop Task Rate Correct Score | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Rate correct score (correct responses·s-¹) on the Incongruent Stroop Task. Higher values indicate better integrated speed-accuracy performance. | ClinicalTrials.gov |
| Secondary | Psychomotor Fatigue Test Reaction Time | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Reaction time (ms) on the Psychomotor Fatigue Test (PFTT). Lower values indicate faster psychomotor processing. | ClinicalTrials.gov |
| Secondary | Psychomotor Fatigue Test Processing Speed | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Processing speed (1000/RT; s-¹) on the PFTT. Higher values indicate faster psychomotor processing. | ClinicalTrials.gov |
| Secondary | Psychomotor Fatigue Test Rate Correct Score | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Rate correct score (correct responses·s-¹) on the PFTT. Higher values indicate better integrated speed-accuracy performance. | ClinicalTrials.gov |
| Secondary | Task-Switching Test Reaction Time | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Reaction time (ms) on the Task-Switching Test (TSWT). Lower values indicate faster cognitive flexibility. | ClinicalTrials.gov |
| Secondary | Task-Switching Test Processing Speed | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Processing speed (1000/RT; s-¹) on the TSWT. Higher values indicate faster cognitive flexibility. | ClinicalTrials.gov |
| Secondary | Task-Switching Test Rate Correct Score | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Rate correct score (correct responses·s-¹) on the TSWT. Higher values indicate better integrated speed-accuracy performance. | ClinicalTrials.gov |
| Secondary | Time-Load Dual-Back Rate Correct Score | Baseline (Week 0) and post-intervention (Week 6) | Rate correct score (correct responses·s-¹) on the 20-minute time-load dual-back (TLDB) mental fatigue induction task. | ClinicalTrials.gov |
| Secondary | Countermovement Jump Peak Landing Force | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Peak landing force (N) assessed via dual force plates (VALD ForceDecks). | ClinicalTrials.gov |
| Secondary | Countermovement Jump Reactive Strength Index | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Reactive strength index (m·s-¹) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular efficiency. | ClinicalTrials.gov |
| Secondary | Countermovement Jump Concentric Impulse | Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction | Concentric impulse (N·s) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater force application during the propulsive phase. | ClinicalTrials.gov |
| Secondary | Pittsburgh Sleep Quality Index - Global Score Change | Change from baseline (Week 0) to post-intervention (Week 6) | Six-week change in PSQI global score stratified by sex and weight status. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Eriksen Flanker Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)